Noxopharm Limited
NOXOF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -60.1% | 10.7% | -3.2% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -22.3% | 97.4% | 95.2% | 95.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -191.6% | -246.3% | -275.3% | -255.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -149.1% | -250.5% | -343.9% | -166.7% |
| EPS Diluted | -0.012 | -0.052 | -0.064 | -0.035 |
| % Growth | 76.3% | 19.7% | -81.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |